Mustang Bio Plans CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

 Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024

MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong foundation for future development in autoimmune disease; pivotal trial for Waldenstrom macroglobulinemia (WM) is expected to initiate in the second half of 2024

https://www.globenewswire.com/news-release/2024/03/28/2854074/0/en/Mustang-Bio-Announces-Vision-for-CAR-T-Cell-Therapy-Platform-Expansion-into-Autoimmune-Diseases.html